Lupin signs licensing, supply agreement with Galenicum

21 Jan 2026 Evaluate

Lupin through its subsidiary -- Lupin Atlantis Holdings SA (LAHSA) has signed licensing and supply agreement with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. 

As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership. 

Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. It is mainly prescribed for adults with Type 2 Diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2176.70 37.30 (1.74%)
22-Jan-2026 12:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1622.40
Dr. Reddys Lab 1222.80
Cipla 1378.85
Zydus Lifesciences 885.05
Lupin 2176.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×